Business Standard

Moderna Covid-19 vaccine stability could give it edge over Pfizer's version

The vaccine is more stable than expected at temperatures that ordinary refrigerators can provide

Premium

The vaccine can be distributed using existing cold-chain shipping and storage infrastructure

Reuters
Moderna Inc’s experimental COVID-19 vaccine is more stable than expected at temperatures that ordinary refrigerators can provide and can be distributed using existing cold-chain shipping and storage infrastructure.

That opens the door for its early use in hard to reach places that might not be appropriate for Pfizer Inc’s vaccine which needs ultra-cold storage.

Here are details of how it could be distributed.

HOW COLD IS COLD STORAGE?
 
Moderna’s vaccine is stable for up to six months at a temperature of minus 20 degrees Celsius (-4 F), about home freezer levels, when shipped and stored.

The company said it expects the vaccine

What you get on BS Premium?

  • Unlock 30+ premium stories daily hand-picked by our editors, across devices on browser and app.
  • Pick your 5 favourite companies, get a daily email with all news updates on them.
  • Full access to our intuitive epaper - clip, save, share articles from any device; newspaper archives from 2006.
  • Preferential invites to Business Standard events.
  • Curated newsletters on markets, personal finance, policy & politics, start-ups, technology, and more.
VIEW ALL FAQs

Need More Information - write to us at assist@bsmail.in